edaravone has been researched along with Disease Exacerbation in 25 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term beneficial effects shown in the MCI186-ALS19 study in a subpopulation in which efficacy was expected." | 9.51 | Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. ( Cordts, I; Dorst, J; Grosskreutz, J; Günther, K; Günther, R; Hagenacker, T; Hermann, A; Koch, B; Koch, JC; Kohl, Z; Lingor, P; Löscher, WN; Ludolph, AC; Maier, A; Meyer, T; Michels, S; Petri, S; Prudlo, J; Ruckes, C; Sarikidi, A; Spittel, S; Steinbach, R; Witzel, S; Wolf, J, 2022) |
| "Edaravone in amyotrophic lateral sclerosis (ALS) was analyzed in two phase 3 studies (MCI186-16 and MCI186-19)." | 9.51 | Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19. ( Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T, 2022) |
| "This was a post hoc analysis of the Edaravone Phase III Study MCI186-19 ('Study 19') to examine the utility of clinical staging systems as end points in clinical trials in amyotrophic lateral sclerosis (ALS)." | 9.41 | Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. ( Agnese, W; Al-Chalabi, A; Apple, S; Bornheimer, R; Chiò, A; Merrill, C; Oster, G, 2021) |
| "In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced significantly less physical functional decline with 24-week edaravone vs placebo, followed by open-label treatment for an additional 24 weeks." | 9.34 | Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). ( Agnese, W; Apple, S; Heiman-Patterson, T; Liu, S; Pioro, EP; Shefner, J; Wiedau-Pazos, M; Zhang, J, 2020) |
| "In this study we examined the relationship between urate levels at baseline and functional change measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score after edaravone treatment." | 8.12 | Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19. ( Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T, 2022) |
| "Using real-world data, the US Department of Veterans Affairs (VA) initiated a surveillance evaluation of edaravone after its approval for amyotrophic lateral sclerosis (ALS) in 2017." | 7.96 | Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System. ( Cunningham, FE; Dong, D; Glassman, PA; Good, CB; Hur, K; Tortorice, K; Vu, M; Zacher, J; Zhang, R, 2020) |
| "Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2." | 7.88 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018) |
| " This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures." | 6.61 | Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. ( Jaiswal, MK, 2019) |
| "Edaravone is an antioxidant free-radical scavenger approved by the FDA in 2017 for the treatment of ALS." | 6.58 | Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion. ( Agnese, W; Brooks, BR; Jorgenson, JA; Newhouse, BJ; Shefner, JM, 2018) |
| "No significant differences on disease progression or respiratory function were found comparing the two cohorts in both descriptive and survival analyses." | 5.56 | The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. ( Calvo, A; Caponnetto, C; D'Ovidio, F; Dubbioso, R; Filippi, M; Giannini, F; Lizio, A; Lunetta, C; Matà, S; Mazzini, L; Moglia, C; Sabatelli, M; Siciliano, G; Simone, IL; Sorarù, G; Toriello, A; Trojsi, F; Vedovello, M, 2020) |
| "Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term beneficial effects shown in the MCI186-ALS19 study in a subpopulation in which efficacy was expected." | 5.51 | Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. ( Cordts, I; Dorst, J; Grosskreutz, J; Günther, K; Günther, R; Hagenacker, T; Hermann, A; Koch, B; Koch, JC; Kohl, Z; Lingor, P; Löscher, WN; Ludolph, AC; Maier, A; Meyer, T; Michels, S; Petri, S; Prudlo, J; Ruckes, C; Sarikidi, A; Spittel, S; Steinbach, R; Witzel, S; Wolf, J, 2022) |
| "Edaravone in amyotrophic lateral sclerosis (ALS) was analyzed in two phase 3 studies (MCI186-16 and MCI186-19)." | 5.51 | Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19. ( Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T, 2022) |
| "This was a post hoc analysis of the Edaravone Phase III Study MCI186-19 ('Study 19') to examine the utility of clinical staging systems as end points in clinical trials in amyotrophic lateral sclerosis (ALS)." | 5.41 | Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. ( Agnese, W; Al-Chalabi, A; Apple, S; Bornheimer, R; Chiò, A; Merrill, C; Oster, G, 2021) |
| "Edaravone treatment significantly reduced messenger RNA expressions of cytokines and matrix metalloproteinases (MMPs) in aneurysm walls (MMP-2: 1." | 5.38 | Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats. ( Hasegawa, T; Morimoto, K; Morimoto, N; Okada, K; Okita, Y; Tanaka, A; Wulan, B; Yu, J, 2012) |
| "In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced significantly less physical functional decline with 24-week edaravone vs placebo, followed by open-label treatment for an additional 24 weeks." | 5.34 | Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). ( Agnese, W; Apple, S; Heiman-Patterson, T; Liu, S; Pioro, EP; Shefner, J; Wiedau-Pazos, M; Zhang, J, 2020) |
| "Edaravone treatment decreased the neutrophil infiltration, the lipid membrane peroxidation, and the expression of proinflammatory cytokine interleukin-6 mRNA in the lungs after intestinal I/R compared to the I/R-treated rat lungs without edaravone treatment." | 5.33 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. ( Horikawa, S; Ito, K; Ozasa, H, 2005) |
| "In this study we examined the relationship between urate levels at baseline and functional change measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score after edaravone treatment." | 4.12 | Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19. ( Kano, O; Nagano, Y; Nelson, S; Takahashi, F; Ushirogawa, Y; Yoneoka, T, 2022) |
| "Using real-world data, the US Department of Veterans Affairs (VA) initiated a surveillance evaluation of edaravone after its approval for amyotrophic lateral sclerosis (ALS) in 2017." | 3.96 | Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System. ( Cunningham, FE; Dong, D; Glassman, PA; Good, CB; Hur, K; Tortorice, K; Vu, M; Zacher, J; Zhang, R, 2020) |
| "Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2." | 3.88 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018) |
| "Rats receiving intracolonic administration of indomethacin develop longitudinal ulcers on the mesenteric side of the small intestine that are similar to those seen in the acute phase of Crohn's disease." | 3.74 | Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats. ( Haruma, K; Iida, M; Koga, H; Shimizu, K, 2007) |
| " This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures." | 2.61 | Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. ( Jaiswal, MK, 2019) |
| "Edaravone is an antioxidant free-radical scavenger approved by the FDA in 2017 for the treatment of ALS." | 2.58 | Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion. ( Agnese, W; Brooks, BR; Jorgenson, JA; Newhouse, BJ; Shefner, JM, 2018) |
| "Edaravone usage data were collected, and adverse events (AEs) were identified from a postmarketing safety database from August 8, 2017 through August 7, 2020 (cutoff date)." | 1.72 | Analysis of the US Safety Data for Edaravone (Radicava ( Apple, S; Bower, L; Brooks, BR; Genge, A; Ji, M; Kalin, A; Oskarsson, B, 2022) |
| "No significant differences on disease progression or respiratory function were found comparing the two cohorts in both descriptive and survival analyses." | 1.56 | The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. ( Calvo, A; Caponnetto, C; D'Ovidio, F; Dubbioso, R; Filippi, M; Giannini, F; Lizio, A; Lunetta, C; Matà, S; Mazzini, L; Moglia, C; Sabatelli, M; Siciliano, G; Simone, IL; Sorarù, G; Toriello, A; Trojsi, F; Vedovello, M, 2020) |
| "Edaravone treatment significantly reduced messenger RNA expressions of cytokines and matrix metalloproteinases (MMPs) in aneurysm walls (MMP-2: 1." | 1.38 | Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats. ( Hasegawa, T; Morimoto, K; Morimoto, N; Okada, K; Okita, Y; Tanaka, A; Wulan, B; Yu, J, 2012) |
| "Edaravone treatment decreased the neutrophil infiltration, the lipid membrane peroxidation, and the expression of proinflammatory cytokine interleukin-6 mRNA in the lungs after intestinal I/R compared to the I/R-treated rat lungs without edaravone treatment." | 1.33 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. ( Horikawa, S; Ito, K; Ozasa, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 12 (48.00) | 2.80 |
| Authors | Studies |
|---|---|
| Witzel, S | 1 |
| Maier, A | 1 |
| Steinbach, R | 1 |
| Grosskreutz, J | 1 |
| Koch, JC | 1 |
| Sarikidi, A | 1 |
| Petri, S | 1 |
| Günther, R | 1 |
| Wolf, J | 1 |
| Hermann, A | 1 |
| Prudlo, J | 1 |
| Cordts, I | 1 |
| Lingor, P | 1 |
| Löscher, WN | 1 |
| Kohl, Z | 1 |
| Hagenacker, T | 1 |
| Ruckes, C | 1 |
| Koch, B | 1 |
| Spittel, S | 1 |
| Günther, K | 1 |
| Michels, S | 1 |
| Dorst, J | 1 |
| Meyer, T | 1 |
| Ludolph, AC | 1 |
| Genge, A | 1 |
| Brooks, BR | 2 |
| Oskarsson, B | 1 |
| Kalin, A | 1 |
| Ji, M | 1 |
| Apple, S | 4 |
| Bower, L | 1 |
| Takahashi, F | 2 |
| Kano, O | 2 |
| Nagano, Y | 2 |
| Yoneoka, T | 2 |
| Nelson, S | 2 |
| Ushirogawa, Y | 2 |
| Johnson, SA | 1 |
| Fang, T | 1 |
| De Marchi, F | 1 |
| Neel, D | 1 |
| Van Weehaeghe, D | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Shefner, J | 1 |
| Heiman-Patterson, T | 1 |
| Pioro, EP | 1 |
| Wiedau-Pazos, M | 1 |
| Liu, S | 2 |
| Zhang, J | 2 |
| Agnese, W | 4 |
| Breiner, A | 1 |
| Zinman, L | 1 |
| Bourque, PR | 1 |
| Barp, A | 1 |
| Gerardi, F | 1 |
| Lizio, A | 2 |
| Sansone, VA | 1 |
| Lunetta, C | 2 |
| Moglia, C | 1 |
| Caponnetto, C | 1 |
| Dubbioso, R | 1 |
| Giannini, F | 1 |
| Matà, S | 1 |
| Mazzini, L | 1 |
| Sabatelli, M | 1 |
| Siciliano, G | 1 |
| Simone, IL | 1 |
| Sorarù, G | 1 |
| Toriello, A | 1 |
| Trojsi, F | 1 |
| Vedovello, M | 1 |
| D'Ovidio, F | 1 |
| Filippi, M | 1 |
| Calvo, A | 1 |
| Vu, M | 1 |
| Tortorice, K | 1 |
| Zacher, J | 1 |
| Dong, D | 1 |
| Hur, K | 1 |
| Zhang, R | 1 |
| Good, CB | 1 |
| Glassman, PA | 1 |
| Cunningham, FE | 1 |
| Al-Chalabi, A | 1 |
| Chiò, A | 1 |
| Merrill, C | 1 |
| Oster, G | 1 |
| Bornheimer, R | 1 |
| Xu, X | 1 |
| Shen, D | 1 |
| Gao, Y | 1 |
| Zhou, Q | 1 |
| Ni, Y | 1 |
| Meng, H | 1 |
| Shi, H | 1 |
| Le, W | 1 |
| Chen, S | 2 |
| Scott, A | 1 |
| Tanahashi, N | 1 |
| Yamaguchi, T | 1 |
| Awano, H | 1 |
| Matsuda, H | 1 |
| Jorgenson, JA | 1 |
| Newhouse, BJ | 1 |
| Shefner, JM | 1 |
| Jaiswal, MK | 1 |
| Abraham, A | 1 |
| Nefussy, B | 1 |
| Fainmesser, Y | 1 |
| Ebrahimi, Y | 1 |
| Karni, A | 1 |
| Drory, VE | 1 |
| Palumbo, JM | 1 |
| Hubble, J | 1 |
| Takei, K | 1 |
| Tsuda, K | 1 |
| Ikeda, K | 1 |
| Iwasaki, Y | 1 |
| Yamakawa, H | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Morimoto, K | 1 |
| Hasegawa, T | 1 |
| Tanaka, A | 1 |
| Wulan, B | 1 |
| Yu, J | 1 |
| Morimoto, N | 1 |
| Okita, Y | 1 |
| Okada, K | 1 |
| Arumugam, S | 1 |
| Thandavarayan, RA | 1 |
| Veeraveedu, PT | 1 |
| Giridharan, VV | 1 |
| Soetikno, V | 1 |
| Harima, M | 1 |
| Suzuki, K | 1 |
| Nagata, M | 1 |
| Tagaki, R | 1 |
| Kodama, M | 1 |
| Watanabe, K | 1 |
| Ito, K | 1 |
| Ozasa, H | 1 |
| Horikawa, S | 1 |
| Maeda, K | 1 |
| Tatsumi, M | 1 |
| Tahara, M | 1 |
| Murata, Y | 1 |
| Kawai, H | 1 |
| Yasuda, H | 1 |
| Shimizu, K | 1 |
| Koga, H | 1 |
| Iida, M | 1 |
| Haruma, K | 1 |
6 reviews available for edaravone and Disease Exacerbation
| Article | Year |
|---|---|
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
Topics: Amyotrophic Lateral Sclerosis; Biological Products; Clinical Trials as Topic; Disease Progression; E | 2022 |
Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Progression; Drug Development; Drug Discovery; Edara | 2020 |
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Disease Management; Disease Progression; Ed | 2021 |
Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Dose-Response Relationship, Drug; Edaravone; Fre | 2018 |
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Clinical Trials as Topic; Disease Models, Anim | 2019 |
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Top | 2019 |
4 trials available for edaravone and Disease Exacerbation
| Article | Year |
|---|---|
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Topics: Administration, Intravenous; Amyotrophic Lateral Sclerosis; Cohort Studies; Disease Progression; Dou | 2022 |
Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blin | 2022 |
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Edaravone; Female; Hu | 2020 |
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Edaravone; Female; Humans; | 2021 |
15 other studies available for edaravone and Disease Exacerbation
| Article | Year |
|---|---|
Analysis of the US Safety Data for Edaravone (Radicava
Topics: Adult; Amyotrophic Lateral Sclerosis; Disease Progression; Dyspnea; Edaravone; Humans; Respiratory I | 2022 |
Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Disease Progression; Edaravone; Free Radica | 2022 |
Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.
Topics: Amyotrophic Lateral Sclerosis; Canada; Compassionate Use Trials; Disease Progression; Drug Costs; Ed | 2020 |
The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Edaravone; Humans; Italy; Treatment Outcome | 2020 |
Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Cohort Studies; Disease Progression; | 2020 |
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Di | 2017 |
Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Diabetes Mellitus; Disability Evaluation; Disea | 2018 |
Early post-marketing experience with edaravone in an unselected group of patients with ALS.
Topics: Aged; Amyotrophic Lateral Sclerosis; Cohort Studies; Disease Progression; Edaravone; Female; Humans; | 2019 |
Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Astrocytes; Disease Models, Animal; Disease Prog | 2015 |
Anterior spinal artery as a collateral channel in patients with acute bilateral vertebral artery occlusions. Two case reports.
Topics: Acute Disease; Aged; Antipyrine; Arginine; Brain Stem; Cerebellum; Cerebral Revascularization; Cereb | 2009 |
Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antipyrine; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apop | 2012 |
Involvement of AMPK and MAPK signaling during the progression of experimental autoimmune myocarditis in rats and its blockade using a novel antioxidant.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antipyrine; Autoimmune Diseases; Disease Models, Anim | 2012 |
Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat.
Topics: Animals; Antipyrine; Disease Progression; Edaravone; Interleukin-6; Intestines; Ischemia; Lung; Male | 2005 |
[A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone].
Topics: Adult; Antipyrine; Brain; Disease Progression; Edaravone; Female; Free Radical Scavengers; Humans; M | 2005 |
Microcirculatory changes in experimental mesenteric longitudinal ulcers of the small intestine in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Cytokines; Disease Models | 2007 |